The mental healthcare system is in desperate need of innovation.
By harnessing the enormous potential of rapid acting psychedelics and digital technology we aim to deliver psychedelic therapies to all those who need them — where and when they need them.
An atai Life Sciences company
Viridia Life Sciences is a biotech company dedicated to developing N,N-Dimethyltryptamine in conjunction with digital therapeutics to deliver efficient, scalable treatments to patients on their own terms.
This pragmatic approach to simplifying DMT administration and the in-clinic treatment paradigm will help people access not only the neurogenic benefits of DMT, but also the personal insights that can accompany psychedelic-assisted psychotherapy… The impact for patients and their families may be transformative.
- Glenn Short
, CEO, Viridia Life Sciences
atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update
NEW YORK and BERLIN, Nov. 10, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today reported financial results for the quarter ended September 30, 2022 and provided a business update.
November 10, 2022
Meet Viridia, the ATAI unit exploring ayahuasca-based treatments for mental illness
Can ayahuasca, a psychoactive brew used traditionally in South America, be used to treat depression and other mental illnesses? Biotech builder ATAI Life Sciences is setting up a subsidiary to find out: Viridia Life Sciences.
July 22, 2020
ATAI Launches Subsidiary Focused On Active Ingredient In Hallucinogenic Brews
Psychedelics and biotech company ATAI Life Sciences announced Wednesday the launch of Viridia Life Sciences.
July 22, 2020